TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Benitec Biopharma Inc.
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma reported positive Phase 1b/2a trial results for BB-301, a gene therapy targeting Oculopharyngeal Muscular Dystrophy (OPMD), with a 100% responder rate. The FDA granted Fast Track Designation, and the company raised $100 million to advance the therapy's development.

Insights
NVDA   positive

Key customer for TSMC's advanced chip production, driving growth through AI and data center GPU demand


BNTC   positive

Achieved 100% responder rate in clinical trial, received FDA Fast Track Designation, successfully raised $100 million in funding, and demonstrated progress in developing a potential first-of-its-kind therapy for OPMD